• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Dupilumab reduces systemic glucocorticoid use in severe asthmatics

byDayton McMillan
July 3, 2018
in Chronic Disease, Emergency, Pediatrics, Pulmonology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. Glucocorticoid dependent severe asthmatics treated with dupilumab for 24 weeks used significantly lower doses of glucocorticoids while maintaining asthmatic control compared to placebo treated patients.

2. Dupilumab treated patients experienced lower rates of severe asthma exacerbations compared to those treated with placebo.

Evidence Rating Level: 1 (Excellent)     

Study Rundown: Patients with severe asthma often utilize systemic glucocorticoids to reduce respiratory inflammation. These agents are nonselective, associated with numerous side effects, and are immunosuppressive. Type 2 inflammation involved in asthma can be more selectively targeted through the interleukin-4 receptor. The monoclonal antibody dupilumab has been used to reduce type 2 inflammation in other inflammatory conditions and has potential to be used in glucocorticoid depended severe asthmatics to reduce glucocorticoid use. This phase 3 randomized study, the LIBERTY ASTHMA VENTURE trial, treated patients with dupilumab and placebo for 24 weeks and found a significant reduction in glucocorticoid use in the dupilumab group, all while asthmatic symptom control was maintained. Dupilumab treated patients also had a lower rate of severe asthma exacerbations and a higher forced expiratory volume in 1 second (FEV1) than those in the placebo group.

Strengths of this study included evaluation of laboratory inflammation markers in addition to clinical markers of efficacy and strong subgroup outcomes analysis. Limitations include a short evaluation period and lack of discussion of treatment cost.

Click to read the study, published in NEJM

RELATED REPORTS

Depemokimab therapy reduces exacerbations in patients with severe eosinophilic asthma

Verona’s Ohtuvayre shows promise in the treatment and management of Chronic Obstructive Pulmonary Disease

Different single inhaler triple therapies appear to have similar clinical outcomes for chronic obstructive pulmonary disease

Relevant Reading: Dupilumab treatment in adults with moderate-to-severe atopic dermatitis

In-Depth [randomized controlled trial]: This phase 3 randomized controlled trial was conducted between 2015 and 2017. Eligible patients were 12 or older and had been receiving systemic glucocorticoids for last 6 months for diagnosed asthma. Patients were randomized to a dupilumab group (n = 103) who received subcutaneous dupilumab biweekly for 24 weeks or a placebo group (n = 107). Glucocorticoids were reduced until they had an increase of 0.5 on the Asthma Control Questionnaire (ACQ-5), a severe exacerbation, or a clinical need for increased glucocorticoids. The primary end-point was percent reduction from baseline to week 24 of glucocorticoid dose while asthma control was maintained. Key secondary outcomes included proportion of patients with at least a 50% reduction in glucocorticoid dose and proportion of patients who used a minimal dose of systemic glucocorticoids.

Glucocorticoids were reduced in the treatment group by 70.1% and in the placebo group by 41.9% (p < 0.001). Reduction in glucocorticoid use by 50% or more occurred in 80% of treatment and 50% of placebo patients (p < 0.001) and use of less than 5mg prednisone a day occurred in 69% of the treatment and 33% of the placebo groups (p < 0.001). Dupilumab was associated with a 59% lower rate of severe asthma exacerbations (95% confidence interval [CI], 37 to 74). FEV1 was an average of 0.22 liters (95% CI, 0.09 to 0.34) higher in the treatment group. Adverse events occurred at similar rates between the two trial groups, with serious adverse events occurring in 9% of treatment and 6% of placebo patients.

Image: PD

©2018 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: asthmacorticosteroidsdupilumab
Previous Post

2 Minute Medicine Rewind July 2, 2018

Next Post

Enzalutamide reduces risk of metastatic prostate cancer in at-risk men

RelatedReports

Teen asthma controller medication adherence affected by risk tolerance
Chronic Disease

Depemokimab therapy reduces exacerbations in patients with severe eosinophilic asthma

March 4, 2025
2 Minute Medicine Rewind May 20, 2019
Pharma

Verona’s Ohtuvayre shows promise in the treatment and management of Chronic Obstructive Pulmonary Disease

January 20, 2025
2 Minute Medicine Rewind May 20, 2019
Chronic Disease

Different single inhaler triple therapies appear to have similar clinical outcomes for chronic obstructive pulmonary disease

January 7, 2025
Chronic Disease

Asthma may be associated with impaired memory function in children

November 21, 2024
Next Post
Patient-reported outcomes differ significantly based on treatment in prostate cancer: The ProtecT trial

Enzalutamide reduces risk of metastatic prostate cancer in at-risk men

Family-support intervention does not significantly improve surrogates’ psychological symptoms: The PARTNER trial

Maternal vaccination during pregnancy not associated with infant hospitalization, mortality

Women who experience hypertensive disorders during pregnancy are at high risk for developing high blood pressure, diabetes, and high cholesterol later in life

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Living in a marginalized neighbourhood is associated with worse outcomes in patients with myocardial infarction
  • SGLT2 inhibitors may delay cognitive impairment in elderly patients with heart failure
  • Nerandomilast slows decline in FVC in idiopathic pulmonary fibrosis
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.